Understanding platinum-induced ototoxicity

Thorsten Langer, Antoinette Am Zehnhoff-Dinnesen, Susanne Radtke, Johannes Meitert, Oliver Zolk*

*Corresponding author for this work
118 Citations (Scopus)


Childhood cancer survival rates are now nearly 80% in more developed European countries because of improved therapies and better supportive care. Platinum chemotherapy drugs, such as cisplatin and carboplatin, are the cornerstone of many effective therapeutic protocols for childhood cancer. However, the antitumor efficacy of cisplatin and carboplatin comes at the cost of ototoxicity, which affects at least 60% of pediatric patients. Although ototoxicity is not life threatening, it can have debilitating effects on patients' quality of life. Recently, many initiatives have been launched with the ultimate goal of reducing cisplatin and high-dose carboplatin ototoxicity without compromising antitumor efficacy. This review addresses the incidence of platinum ototoxicity and its clinical presentation, time course, and early diagnostic evaluation. Genetic and non-genetic risk factors for platinum-associated ototoxicity, and their predictive value, are discussed. Recent developments in the prevention of platinum ototoxicity are also summarized.

Original languageEnglish
JournalTrends in Pharmacological Sciences
Issue number8
Pages (from-to)458-469
Number of pages12
Publication statusPublished - 08.2013

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)


Dive into the research topics of 'Understanding platinum-induced ototoxicity'. Together they form a unique fingerprint.

Cite this